![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Tesla
TSLA
Strategy
MSTR
Coinbase
COIN
MARA Holdings
MARA
Taylor Morrison Home
TMHC
US Stock MarketDetailed Quotes
MLTX MoonLake Immunotherapeutics
- 39.450
- -0.200-0.50%
Trading Mar 19 09:40 ET
2.50BMarket Cap-20.87P/E (TTM)
39.870High39.450Low3.97KVolume39.450Open39.650Pre Close156.72KTurnover0.01%Turnover RatioLossP/E (Static)63.28MShares58.26052wk High5.59P/B1.11BFloat Cap36.52052wk Low--Dividend TTM28.21MShs Float64.980Historical High--Div YieldTTM1.06%Amplitude4.250Historical Low39.525Avg Price1Lot Size
MoonLake Immunotherapeutics Stock Forum
Sign in to post a comment
Morning Movers
Gapping up
$Qorvo (QRVO.US)$ saw a 7% increase after reports of activist investor Starboard Value acquiring a 7.7% stake.
$MoonLake Immunotherapeutics (MLTX.US)$ gained over 4% following Goldman Sachs' upgrade to 'buy', citing positive expectations for its phase 3 trial data.
$Life360 (LIF.US)$ rose 3% following UBS's upgrade to 'buy', based on promising ad revenue potential.
$Rivian Automotive (RIVN.US)$ increased 2...
Gapping up
$Qorvo (QRVO.US)$ saw a 7% increase after reports of activist investor Starboard Value acquiring a 7.7% stake.
$MoonLake Immunotherapeutics (MLTX.US)$ gained over 4% following Goldman Sachs' upgrade to 'buy', citing positive expectations for its phase 3 trial data.
$Life360 (LIF.US)$ rose 3% following UBS's upgrade to 'buy', based on promising ad revenue potential.
$Rivian Automotive (RIVN.US)$ increased 2...
24
4
16
$Pfizer (PFE.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$Vera Therapeutics (VERA.US)$ Phase 2b
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$Akero Therapeutics (AKRO.US)$ Phase 2b
$Spruce Biosciences (SPRB.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Annexon (ANNX.US)$ Phase 2a
$Roivant Sciences (ROIV.US)$...
$Leap Therapeutics (LPTX.US)$ Phase 2
$Vera Therapeutics (VERA.US)$ Phase 2b
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$Akero Therapeutics (AKRO.US)$ Phase 2b
$Spruce Biosciences (SPRB.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Annexon (ANNX.US)$ Phase 2a
$Roivant Sciences (ROIV.US)$...
26
1
$Cellectar BioSciences (CLRB.US)$ Phase 2
$Regenxbio (RGNX.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals (EYPT.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Disc Medicine (IRON.US)$ Phase 2
$Atea Pharmaceuticals (AVIR.US)$ Phase 2
$Allakos (ALLK.US)$ Phase 2 ...
$Regenxbio (RGNX.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals (EYPT.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Disc Medicine (IRON.US)$ Phase 2
$Atea Pharmaceuticals (AVIR.US)$ Phase 2
$Allakos (ALLK.US)$ Phase 2 ...
40
9
1
MoonLake's CEO expresses confidence in 120mg being the optimal dose and highlights the drug's improved durability of response compared to Humira in other studies.
The long stock would be $Bruush Oral Care (BRSH.US)$. First its goal is to regain compliance over a 1.00. Second it has a new line of products to boost its next ER. Third the upside beats the downside. 500% in gains.
The short stock would be $MoonLake Immunotherapeutics (MLTX.US)$ It has just seen its highest run. Once it gets above 50.00 its loses investors interest.
The short stock would be $MoonLake Immunotherapeutics (MLTX.US)$ It has just seen its highest run. Once it gets above 50.00 its loses investors interest.
11
13
$Applied Optoelectronics (AAOI.US)$ $Astrotech (ASTC.US)$ $AstraZeneca (AZN.US)$ $Charter Communications (CHTR.US)$ $FibroGen (FGEN.US)$ $Leap Therapeutics (LPTX.US)$ $Lulus Fashion Lounge (LVLU.US)$ $Trxade Health (MEDS.US)$ $MoonLake Immunotherapeutics (MLTX.US)$ $Netflix (NFLX.US)$ $Paltalk (PALT.US)$ $Praxis Precision Medicines (PRAX.US)$ $Pioneer Natural Resources (PXD.US)$ $ReShape Lifesciences (RSLS.US)$ $Acelyrin (SLRN.US)$
2
1
$MoonLake Immunotherapeutics (MLTX.US)$ I have this skin condition, Hopefully they keep having good results with their medication. Hopefully this stock really flies again off this news.
No comment yet
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Buy n Die Together❤ :
Jin Chen269 :![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
安稳的利奥 Jin Chen269 :![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
勇敢M00M00_不怕翻车 安稳的利奥 :![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")